NiaHealth
Category: AI in Healthcare
A digital therapy platform and app that helps patients manage chronic skin conditions like neurodermatitis (atopic dermatitis), psoriasis, and acne. NiaHealth was founded in 2019. The company is led by Tobias Seidl. Based in Berlin, Germany. Team size: 11-50. Total funding raised: €3.5 Million. Latest round: Seed, €3.5M, 2023-05, led by High-Tech Gründerfonds. Key investors include High-Tech Gründerfonds (HTGF), adesso ventures, Ventura BioMed Investors.
- Founded
- 2019
- Headquarters
- Berlin, Germany
- Team size
- 11-50
- Total funding
- €3.5 Million
Value proposition
Empowers patients to better understand and manage their condition through AI-powered flare-up prediction, photo documentation, and personalized recommendations, leading to improved outcomes and reduced healthcare costs.
Products and solutions
Nia Neurodermitis App, Sorea Psoriasis App, milderma (acne app)
Unique value
NiaHealth is a spin-off from the Charité Universitätsmedizin Berlin, combining medical expertise with AI technology. Its core innovation is a multi-modal AI that analyzes patient-recorded data (triggers, symptoms, photos) to provide personalized insights and predict flare-ups.
Target customer
Patients with chronic skin conditions, dermatologists, and health insurance providers.
Industries served
Healthcare, Digital Therapeutics
Technology advantage
Official status as a DiGA (Digital Health Application) in Germany allows doctors to prescribe the app, with costs covered by statutory health insurance. Proprietary AI for image analysis and flare-up prediction.
How they differentiate
NiaHealth focuses on the daily management of chronic inflammatory skin diseases rather than one-off mole checks or general teledermatology. Its DiGA status provides a strong competitive advantage in the German market through prescription-based reimbursement.
Main competitors
SkinVision, First Derm, Cureai
Key partnerships
Charité – Universitätsmedizin Berlin, Sanofi, LEO Pharma, BARMER, Techniker Krankenkasse (TK), Deutscher Psoriasis Bund (German Psoriasis Association)
Notable customers
The app is prescribable by doctors and reimbursed by all statutory health insurers in Germany.
Major milestones
Successfully listed the 'Nia Neurodermitis App' in the German DiGA directory. Spun out of Europe's largest university hospital, Charité – Universitätsmedizin Berlin. Closed €3.5M seed financing round to scale its platform. Launched 'Sorea' app for psoriasis and 'milderma' for acne.
Growth metrics
The 'Nia Neurodermitis App' is the most downloaded app for atopic dermatitis in German-speaking countries.
Market positioning
Leading digital therapy provider for atopic dermatitis in the German-speaking market, with a focus on prescription-based digital health applications.
Geographic focus
Primarily German-speaking countries (DACH region), with plans for European and US expansion.
Patents and IP
Information not publicly available
About Tobias Seidl
Tobias Seidl is a seasoned entrepreneur and business leader with extensive experience spanning health technology, consulting, and entrepreneurship. As Co-Founder and CEO of Nia Health GmbH, he focuses on developing innovative, personalized medical software solutions aimed at improving patient outcomes in dermatology and allergology. His leadership drives the integration of clinical validation, empowerment, gamification, and machine learning in digital therapeutics. Before Nia Health, Tobias co-founded Biodirekt GmbH and held key roles in business development and consulting at companies including Bonativo (Rocket Internet SE), Kienbaum, and Deloitte. His broad background also includes marketing and sales roles, providing a comprehensive understanding of market dynamics, consumer behavior, and strategic business growth.
Official website: https://www.nia-health.com/